Translational advances and novel therapies for pancreatic ductal adenocarcinoma: Hope or hype?

Expert Reviews in Molecular Medicine

Volumn 11, Issue , 2009, Pages

  Chandana, Sreenivasa ^a   Mahadevan, Daruka ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; GENETICS; HUMAN; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELL CULTURE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 77951628026     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399409001240     Document Type: Review

References (165)

1. Jemal, A. et al. (2007) Cancer Statistics. CA Cancer Journal of the Clinic 57, 43-66
2. Klein, A.P. et al. (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Research 64, 2634-2639
3. Lowenfels, A.B. et al. (2001) Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. Journal of the American Medical Association 286, 169-170 (Pubitemid 32640846)
4. Lowenfels, A.B. et al. (1993) Pancreatitis and the risk of pancreas cancer. International Pancreatitis Study Group. New England Journal of Medicine 328, 1433-1437 (Pubitemid 23143844)
5. Gullo, L., Pezzilli, R. and Morselli-Labate, A.M. (1994) Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group. New England Journal of Medicine 331, 81-84 (Pubitemid 24202222)
6. Everhart, J. andWright, D. (1995) Diabetes mellitus as a risk factor for pancreatic cancer. A meta analysis. Journal of the American Medical Association 273, 1605-1609
7. Permert, J. et al. (1993) Improved glucose metabolism after subtotal pancreatectomy for pancreas cancer. British Journal of Surgery 80, 1047-1050 (Pubitemid 23261595)
8. Canto, M.I. (2007) Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Seminars in Oncology 34, 295-302
9. Neoptolemos, J.P. et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreas cancer.NewEngland Journal of Medicine 350, 1200-1210 (Pubitemid 38339364)
10. Alexakis, N. et al. (2004) Current standards of surgery for pancreatic cancer. British Journal of Surgery 91, 1410-1427 (Pubitemid 39518076)
11. Kim, H.J. et al. (2002) Does neoadjuvant chemoradiation downstage locally advanced pancreas cancer? Journal of Gastrointestinal Surgery 6, 763-769 (Pubitemid 40433496)
12. Oettle, H. and Neuhaus, P. (2007) Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs 67, 2293-2310 (Pubitemid 350071043)
13. Burris, H.A. et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. Journal of Clinical Oncology 15, 2403-2413
14. Cartwright, T., Richards, D.A. and Boehm, K.A. (2008) Cancer of the pancreas: are we making progress? a review of studies in the US Oncology Research Network. Cancer Control 15, 308-313
15. Von Hoff, D.D. (2006) What's new in pancreatic cancer treatment pipeline? Best Practice & Research: Clinical Gastroenterology 20, 315-26
16. Rubio-Viqueira, B. et al. (2006) An in vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Research 12, 4652-4661 (Pubitemid 44297818)
17. Olive, K.P. and Tuveson, D.A. (2006) The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clinical Cancer Research 12, 5277-5287 (Pubitemid 44497240)
18. Jones, S., Zhang, X. and Parsons, D.W. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806
19. Han, H. et al. (2002) Identification of differentially expressed genes in pancreatic cancer cells using cdna microarray. Cancer Research 62, 2890-2896 (Pubitemid 34525776)
20. Crnogorac-Jurcevic, T. et al. (2002) Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21, 4587-4594 (Pubitemid 34785735)
21. Iacobuzio-Donahue, C.A. et al. (2003) Exploration of global gene expression patterns in pancreatic adenocarcinoma using cdna microarrays. American Journal of Pathology 162, 1151-1162 (Pubitemid 36350660)
22. Iacobuzio-Donahue, C.A. et al. (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Research 63, 8614-8622 (Pubitemid 38064035)
23. Campagna, D. et al. (2008) Gene expression profiles associated with advanced pancreatic cancer. International Journal of Clinical Experimental Pathology 1, 32-43
24. Mahadevan, D. and Von Hoff, D.D. (2007) Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Molecular Cancer Therapeutics 6, 1186-1197 (Pubitemid 46711982)
25. Apte, M.V. et al. (2004) Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29, 179-187 (Pubitemid 39304974)
26. Menke, A. and Adler, G. (2002) TGFbeta-induced fibrogenesis of the pancreas. International Journal of Gastrointestinal Cancer 31, 41-46
27. Infante, J.R., Matsubayashi, H. and Sato, N. (2007) Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. Journal of Clinical Oncology 25, 319-25 (Pubitemid 350003021)
28. Hruban, R.H. et al. (2000) Progression model for pancreatic cancer. Clinical Cancer Research 6, 2969-2972 (Pubitemid 30637716)
29. Maitra, A. et al. (2005) Precursors to invasive pancreatic cancer. Advances in Anatomic Pathology 12, 81-91 (Pubitemid 40515796)
30. Ishikawa, O. et al. (1999) Minute carcinoma of the pancreas measuring 1 cm or less in diameter - Collective review of Japanese case reports. Hepatogatroenterology 46, 8-15 (Pubitemid 29154713)
31. Gangi, S. et al. (2004) Time interval between abnormalities seen on CTand the clinical diagnosis of pancreatic cancer. Retrospective review of CT scans obtained before diagnosis. American Journal of Roentgenology 182, 897-903 (Pubitemid 38391649)
32. Benson, A.B. et al. (2003) Pancreatic, neuroendocrine GI and adrenal cancers. In Cancer Management: A Multidisciplinary Approach (7th edn) (Pazdur R. et al., eds), pp. 273-302, CMP Medica
33. Bissell, M.J. and Radisky, D. (2001) Putting tumors in context. Nature Reviews Cancer 1, 46-54
34. Chifenti, B. et al. (2008) Establishment and characterization of 4 new human pancreatic cancer cell lines. Evidences of different tumor phenotypes. Pancreas 38, 184-196
35. Bruns, C.J. et al. (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clinical Cancer Research 6, 1936-1948 (Pubitemid 30305093)
36. Riley, C.J. et al. (2009) Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Research 69, 1933-1940
37. Hingorani, S.R. et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (Pubitemid 38050041)
38. Aguirre, A.J. et al. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Development 17, 3112-3126 (Pubitemid 38040774)
39. Hingorani, S.R. et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (Pubitemid 40719130)
40. Izeradjene, K. et al. (2007) KrasG12D and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11, 299-243
41. Takaku, K. et al. (1998) Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92, 645-656 (Pubitemid 28141513)
42. Velculescu, V.E. et al. (1995) Serial analysis of gene expression. Science 270, 484-487
43. Kim, H.N. et al. (2007) Gene expression profiling in lymph node-positive and lymph-node negative pancreatic cancer. Pancreas 34, 325-334 (Pubitemid 46588258)
44. Collisson, E.A. et al. (2008) Use of whole genome expression analysis of pancreatic adenocarcinoma to predict prognosis after surgery. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4503
45. Mori, R. et al. (2008) Different pancreatic cancer genomic risk prediction models derived from microdissected and non-microdissected paraffin-embedded tissue. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4622
46. Bonnet, D. and Dick, J.E. (1997) Human acute myeloid leukemia is organized as a hierachy that originates from a primitive hematopoietic cell. Nature Medicine 3, 730-737 (Pubitemid 27298715)
47. Al-Hajj, M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 100, 3983-3988 (Pubitemid 36418143)
48. Simeone, D.M. (2008) Pancreatic cancer stem cells: implications for the treatment of pancreas cancer. Clinical Cancer Research 14, 5646-5648
49. Li, C. et al. (2007) Identification of pancreatic cancer stem cells. Cancer Research 67, 1030-1037
50. Hermann, P.C. et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreas cancer. Cell Stem Cell 1, 313-323 (Pubitemid 47355323)
51. American Joint Committee on Cancer. (2002) Exocrine pancreas. In American Joint Committee on Cancer: AJCC Cancer Staging Manual (6th edn), pp. 157-164, Springer, New York, USA
52. Katz, M.H. et al. (2008) Tumor-node-metastasis staging of pancreatic adenocarcinoma. Cancer Journal of the Clinic 58, 111-125 (Pubitemid 351521866)
53. Katz, M.H. et al. (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. Journal of the AmericanCollege of Surgery 206, 833-846
54. Glanemann, M. et al. (2008) Surgical strategies for treatment of malignant pancreas tumors: extended, standard or local surgery? World Journal of Surgical Oncology 6, 1-10
55. Ujiki, M.B. and Talamonti, M.S. (2007) Guidelines for the surgical management of pancreatic adenocarcinoma. Seminars in Oncology 34, 311-320 (Pubitemid 47176619)
56. Tanaka, M. (2004) Intraductal papillary mucinous neoplasm of the pancreas. Pancreas 28, 282-288
57. Levy, M.J. et al. (2005) Endoscopic ultrasound-guided trucut biopsy of the cyst wall for diagnosing cystic pancreatic tumors. Clinical Gastroenterology and Hepatology 3, 974-979 (Pubitemid 41415744)
58. Moore, M.J. et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 25, 1960-1966 (Pubitemid 46972777)
59. O'Reilly, E.M. and Abou-Alfa, G.K. (2007) Cytotoxic therapy for advanced pancreatic adenocarcinoma. Seminars in Oncology 34, 347-353 (Pubitemid 47176624)
60. Pelzer, U. et al. (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4508
61. Poplin, E. et al. (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 27, 3778-3785
62. Vervenne, W. et al. (2008) A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4507
63. Von Hoff, D.D., Mahadevan, D. and Bearss, D.J. (2001) New developments in the treatment of patients with pancreatic cancer. Clinical Oncology Updates 4, 1-15
64. Burtness, B.A. et al. (2007) Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor (EGF-r): Eastern Cooperative Oncology. Journal of Clinical Oncology 25 (June 20 Suppl: ASCOAnnualMeetings Proceedings),Abstract 4519
65. Drengler, R.L. et al. (2008) Phase I study of nabpaclitaxel and gemcitabine combination in patients with advanced pancreatic cancer. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 15523
66. Smith, L.S. et al. (2008) SPARC and CA19-9 as biomarkers in patients with advanced pancreatic cancer treated with nab paclitaxel plus gemcitabine. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 15592
67. Löhr, M. et al. (2009) A phase II trial of cationic liposomal paclitaxel in combination with gemcitabine in patientswith unresectable pancreatic cancer. 2009 ASCO Gastrointestinal Cancers Symposium, Abstract LBA120, http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=63&abstractID=10270
68. Berman, D.M. et al. (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846-851 (Pubitemid 37351469)
69. Taipale, J. and Beachy, P.A. (2001) The Hedgehog and Wnt signaling pathways in cancer. Nature 411, 349-354 (Pubitemid 32467044)
70. Thayer, S.P. et al. (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425, 851-856 (Pubitemid 37355945)
71. Morton, J.P. et al. (2007) Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 104, 5103-5108 (Pubitemid 47186183)
72. Prasad, N.B. et al. (2005) Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Research 65, 1619-1626 (Pubitemid 40478583)
73. Pasca di Magliano, M. and Hebrok, M. (2003) Hedgehog signaling in cancer formation and maintenance. Nature Review Cancer 3, 903-911
74. Ji, Z. et al. (2007) Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. Journal of Biological Chemistry 282, 14048-14055 (Pubitemid 47100411)
75. Nolan-Stevaux, O. et al. (2008) GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes and Development 23, 24-36
76. Yauch, R.L. et al. (2008) A paracrine requirement for hedgehog signaling in cancer. Nature 455, 406-410
77. Feldmann, G. et al. (2007) Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Research 67, 2187-2196 (Pubitemid 46424238)
78. Jimeno, A. et al. (2009) A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Molecular Cancer Therapeutics 8, 310-314
79. LoRusso, P.M. et al. (2008) A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 26 (May 20 Suppl: ASCOAnnualMeetings Proceedings),Abstract 3516
80. Travaglione, V. et al. (2008) Activity of IPI-926, a novel inhibitor of theHhpathway, in subcutaneous and orthotopically implanted xenograft tumors that express SHh ligand. Presented at the EORTCNCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (21-24 October 2008; Geneva, Switzerland), poster 570, http://www.infi.com/pipeline-archives/INFI%20IPI- 926%20tumor%20stroma%20-%20EORTC%202008.pdf
81. Iacobuzio-Donahue, C.A. et al. (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. Journal of Clinical Oncology 27, 1806-1813
82. Singh, J. et al. (2003) Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorganismal Medicine Chemistry Letters 13, 4355-4359 (Pubitemid 37490817)
83. Melisi, D. et al. (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Molecular Cancer Therapeutics 7, 829-840 (Pubitemid 351551036)
84. Gaspar, N.J. et al. (2007) Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Molecular Pharmacology 72, 152-161 (Pubitemid 46998534)
85. Ottaviano, A.J. et al. (2006) Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Research 66, 7032-7040 (Pubitemid 44197679)
86. Ohuchida, K. et al. (2004) Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Research 64, 3215-3222 (Pubitemid 38581425)
87. Michieli, P. et al. (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73 (Pubitemid 38903162)
88. Garber, K. (2007) Notch emerges as new cancer drug target. Journal of the National Cancer Institute 99, 1284-1285
89. Wang, Z. et al. (2006) Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Molecular Cancer Therapeutics 5, 483-493
90. Iseki, H. et al. (1998)A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. Journal of Gastrointestinal Surgery 2, 36-43 (Pubitemid 128423462)
91. Howard, S. et al. (2009) Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. Journal of Medicinal Chemistry 52, 379-88
92. Ashwell, S., Janetka, J.W. and Zabludoff, S. (2008) Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opinion on Investigational Drugs 17, 1331-1340
93. Ito, D. et al. (2006) In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. International Journal of Cancer 118, 2337-2343
94. Wolpin, B.M. et al. (2009) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. Journal of Clinical Oncology 27, 193-198
95. Engelhardt, K. et al. (2006) Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma. Current Drug Discovery Technology 3, 231-243 (Pubitemid 46578058)
96. Wenger, C. et al. (1999) Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 18, 1073-1080 (Pubitemid 29086285)
97. Ryu, B. et al. (2001) Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Research 61, 1833-1838 (Pubitemid 32691994)
98. Dornhöfer, N. et al. (2006) Connective tissue growth factor specific mAb therapy inhibits pancreatic tumor growth and metastasis. Cancer Research 66, 5817-5827
99. Burns, W.C. et al. (2006) Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. Journal of the American Society of Nephrology 17, 2484-2494 (Pubitemid 44300964)
100. Thomas, R.M. et al. (2007) The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreas cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Research 67, 6075-6082 (Pubitemid 47037486)
101. O'Toole, J.M. et al. (2006) Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-Met family member. Cancer Research 66, 9162-9170 (Pubitemid 44521136)
102. Bauer, T.W. et al. (2005) Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met and insulin-like growth factor-1 receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Research 65, 7775-7781 (Pubitemid 41297252)
103. Stahel, R.A. and Zangemeister-Wittke, U. (2003) Antisense oligonucleotides for cancer therapy-an overview. Lung Cancer 41 (Suppl 1), S81-8 (Pubitemid 36818999)
104. Jolivet, J. et al. (2008) A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 3541
105. Seymour, A.B. et al. (1994) Allelotype of pancreatic adenocarcinoma. Cancer Research 54, 2761-2764 (Pubitemid 24173771)
106. Clark, C.E. et al. (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Research 67, 9518-9527 (Pubitemid 47535942)
107. Clark, C.E., Beatty, G.L. and Vonderheide, R.H. (2009) Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Letters 279, 1-7
108. Masamune, A. et al. (2009) Fibronogen induces cytokine and collagen production in pancreatic stellate cells. Gut 58, 550-559
109. Hwang, R.F. et al. (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Research 68, 918-926 (Pubitemid 351206771)
110. Bailey, J.M. et al. (2008) Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clinical Cancer Research 14, 5995-6004
111. Bipat, S. et al. (2005) Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. Journal of Computer Assisted Tomography 29, 438-445 (Pubitemid 41060274)
112. Dewitt, J. et al. (2006) Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clinical Gastroenterology and Hepatology 4, 717-725
113. Farma, J.M. et al. (2007) PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Annals of Surgical Oncology 15, 2465-2471
114. Levy, M.J. (2007) Endoscopic ultrasound-guided Trucut biopsy of the pancreas: prospects and problems. Pancreatology 7, 163-166
115. Mertz, H.R. et al. (2000) EUS, PET, and CTscanning for evaluation of pancreatic adenocarcinoma. Gastrointestinal Endoscopy 52, 367-371
116. Chari, S.T. et al. (2007) Detecting early pancreatic cancer: problems and prospects. Seminars in Oncology 34, 284-294 (Pubitemid 47176620)
117. Canto, M.I. et al. (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clinical Gastroenterology and Hepatology 4, 766-781 (Pubitemid 43825802)
118. Fukushima, H. et al. (2006) Diagnostic value of curved multiplanar reformatted images in multislice CT for the detection of resectable pancreatic ductal adenocarcinoma. European Radiology 16, 1709-1718 (Pubitemid 44027372)
119. Chang, K.J. (2006) State of the art lecture: endoscopic ultrasound (EUS) and FNA in pancreatico-biliary tumors. Endoscopy 38 (Suppl 1), S56-S60
120. Brand, R.E. et al. (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56, 1460-1469 (Pubitemid 47517845)
121. Rosch, T. et al. (2000) Endoscopic ultrasound criteria for vascular invasion in the staging of cancer of the head of the pancreas: a blind reevaluation of videotapes. Gastrointestinal Endoscopy 52, 469-477
122. Meining, A. et al. (2002) You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging. Gut 50, 599-603 (Pubitemid 34407483)
123. Meining, A. et al. (2003) High interobserver variability in endosonographic staging of upper gastrointestinal cancers. Gastroenterology 41, 391-394 (Pubitemid 36686905)
124. Beyer, T., Townsend, D.W. and Blodgett, T.M. (2002) Dual-modality PET/CT tomography for clinical oncology. Quarterly Journal of Nuclear Medicine 46, 24-34 (Pubitemid 34808736)
125. Heinrich, S. et al. (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Annals of Surgery 242, 235-243 (Pubitemid 41033440)
126. Kashiwagi, H. et al. (2007) Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Molecular Cancer 15, 6-48
127. Shields, A.F. et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Medicine 4, 1334-1336 (Pubitemid 28512118)
128. Herrmann, K. et al. (2008) In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. Journal of Nuclear Medicine 49, 1437-1444
129. Mitsuoka, K. et al. (2008) Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H +/peptide transporter. Journal of Nuclear Medicine 49, 615-622 (Pubitemid 351520610)
130. Weissleder, R. and Pittet, M.J. (2008) Imaging in the era of molecular oncology. Nature 452, 580-589 (Pubitemid 351483372)
131. Min, J.J. and Gambhir, S.S. (2008) Molecular imaging of PET reporter gene expression. Handbook of Experimental Pharmacology 185, 277-303
132. Kelly, K.A. et al. (2008) Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Medicine 5, e85
133. Hamanaka, Y. et al. (2003) Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. International Journal of Cancer 103, 97-100
134. Raedle, J. et al. (1996) p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 13, 241-246 (Pubitemid 26317992)
135. Maacke, H. et al. (2002) Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. Journal of Cancer Research in Clinical Oncology 128, 219-222 (Pubitemid 34280380)
136. Xia, Q. et al. (2005) Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochemistry and Biophysics Research Community 330, 526-532 (Pubitemid 40417676)
137. Koopmann, J. et al. (2004) Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention 13, 487-491 (Pubitemid 38737477)
138. Koopmann, J. et al. (2004) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clinical Cancer Research 10, 2386-2392 (Pubitemid 38445697)
139. Koopmann, J. et al. (2006) Serummarkers inpatients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clinical Cancer Research 12, 442-446 (Pubitemid 43166133)
140. Simeone, D.M. et al. (2007) CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34, 436-443 (Pubitemid 46725785)
141. Koopmann, J. et al. (2004) Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clinical Cancer Research 10, 860-868 (Pubitemid 38198884)
142. Argani, P. et al. (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clinical Cancer Research 7, 3862-3868 (Pubitemid 34044602)
143. Faca, V.M. et al. (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Medicine 5, e123
144. Goggins, M. (2007) Identifying molecular markers for the early detection of pancreatic neoplasia. Seminars in Oncology 34, 303-310
145. Gronborg, M. et al. (2004) Comprehensive proteomic analysis of human pancreatic juice. Journal of Protein Research 3, 1042-1055 (Pubitemid 39425662)
146. Chen, R. et al. (2006) Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 6, 3871-3879 (Pubitemid 44065164)
147. Chen, R. et al. (2007) Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 34, 70-79 (Pubitemid 46045723)
148. Zhou, L. et al. (2007) Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics 7, 1345-1355 (Pubitemid 46716055)
149. Zhao, J. et al. (2007) Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. Journal of Proteome Research 6, 1864-1874 (Pubitemid 46814510)
150. Lu, J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (Pubitemid 40839735)
151. Bittner, M. et al. (2006) Frequency of potential therapeutic targets identified by immnuohistochemistry and DNA microarray in tumors from patients who have progressed on multiple therapeutic agents. Journal of Clinical Oncology 24, 18s-138s
152. Olive, K.P. et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461
153. Elroy, M. et al. (2008) Color-coded imaging of splenocyte-pancreatic cancer cell interactions in the tumor microenvironment. Cell Cycle 7, 2916-2921
154. Mueller, M-T. et al. (2009) Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137, 1102-1113
155. Deramaudt, T.B. et al. (2006) N-Cadherin and keratinocyte growth factor receptor mediate the functional interplay between Ki-Ras G12Vand p53 V143A in promoting pancreatic cell migration, invasion and tissue architecture disruption. Molecular and Cellular Biology 26, 4185-4200 (Pubitemid 43788020)
156. Kuang, C. et al. (2006) In vivo disruption of TGF-βsignaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proceedings of the National Academy of Sciences of the United States of America 103, 1858-1863 (Pubitemid 43228783)
157. Cindy, Y.F. et al. (2005) Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Research 65, 1497-1504
158. Fuhrman, G. et al. (1994) Thin section contrast enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms.AmericanJournalofSurgery167,104-113 (Pubitemid 24264151)
159. Moertel, C.G. et al. (1981) Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5- fluorouracil) and high dose radiation + 5- fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48, 1705-1710 (Pubitemid 11022870)
160. Chauffert, B. et al. (2008) Phase III trial comparing intensive induction chemotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Annals of Oncology 19, 1592-1599
161. Kalser, M.H. and Ellenberg, S.S. (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Archives of Surgery 120, 899-903 (Pubitemid 15040883)
162. Regine, W.F. et al. (2006) RTOG 9704 a Phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine for resected pancreatic adenocarcinoma. Journal of Clinical Oncology 24 (June 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4007
163. Oettle, H. et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized control trial. Journal of the American Medical Association 297, 267-277 (Pubitemid 46143304)
164. Neuhaus, P. et al. (2008) CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings) Abstract LBA4504
165. Loehrer, P.J. et al. (2008) A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4506